Nonimmunosuppressive therapy of membranous nephropathy

Arrigo Schieppati, Piero Ruggenenti, Annalisa Perna, Giuseppe Remuzzi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.

Original languageEnglish
Pages (from-to)333-339
Number of pages7
JournalSeminars in Nephrology
Volume23
Issue number4
Publication statusPublished - Jul 2003

Fingerprint

Membranous Glomerulonephritis
Proteinuria
Spontaneous Remission
Nephrotic Syndrome
Immunosuppressive Agents
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Chronic Kidney Failure
Meta-Analysis
Therapeutics
Steroids
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

Nonimmunosuppressive therapy of membranous nephropathy. / Schieppati, Arrigo; Ruggenenti, Piero; Perna, Annalisa; Remuzzi, Giuseppe.

In: Seminars in Nephrology, Vol. 23, No. 4, 07.2003, p. 333-339.

Research output: Contribution to journalArticle

Schieppati, A, Ruggenenti, P, Perna, A & Remuzzi, G 2003, 'Nonimmunosuppressive therapy of membranous nephropathy', Seminars in Nephrology, vol. 23, no. 4, pp. 333-339.
Schieppati, Arrigo ; Ruggenenti, Piero ; Perna, Annalisa ; Remuzzi, Giuseppe. / Nonimmunosuppressive therapy of membranous nephropathy. In: Seminars in Nephrology. 2003 ; Vol. 23, No. 4. pp. 333-339.
@article{ba5d8a9c4e384d78a7ff94c48105248a,
title = "Nonimmunosuppressive therapy of membranous nephropathy",
abstract = "Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.",
author = "Arrigo Schieppati and Piero Ruggenenti and Annalisa Perna and Giuseppe Remuzzi",
year = "2003",
month = "7",
language = "English",
volume = "23",
pages = "333--339",
journal = "Seminars in Nephrology",
issn = "0270-9295",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Nonimmunosuppressive therapy of membranous nephropathy

AU - Schieppati, Arrigo

AU - Ruggenenti, Piero

AU - Perna, Annalisa

AU - Remuzzi, Giuseppe

PY - 2003/7

Y1 - 2003/7

N2 - Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.

AB - Idiopathic membranous nephropathy (MN) has a variable rate of progression to end-stage renal failure, with a significant number of patients going into spontaneous remission without therapy. For those who have persistent nephrotic proteinuria or manifest deterioration of renal function, steroids and immunosuppressive drugs are used. However, their long-term efficacy is challenged by a meta-analysis presented here. A different approach to reduction of proteinuria, a recognized progression promoter, is based on the notion that angiotensin II inhibition controls proteinuria and slows progression. Further, a more complex approach is required than simple administration of an angiotensin-converting enzyme (ACE) inhibitor: a multidrug approach to remission of nephrotic syndrome therefore is described here.

UR - http://www.scopus.com/inward/record.url?scp=0042889562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042889562&partnerID=8YFLogxK

M3 - Article

C2 - 12923721

AN - SCOPUS:0042889562

VL - 23

SP - 333

EP - 339

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 4

ER -